Avacta Group Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Avacta Group's earnings have been declining at an average annual rate of -20.7%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 45.6% per year.
Belangrijke informatie
-20.7%
Groei van de winst
-7.7%
Groei van de winst per aandeel
Biotechs Groei van de industrie | 11.5% |
Inkomstengroei | 45.6% |
Rendement op eigen vermogen | -53.7% |
Nettomarge | -114.4% |
Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Is Avacta Group (LON:AVCT) Using Debt Sensibly?
Oct 29Avacta Group Plc's (LON:AVCT) 29% Share Price Surge Not Quite Adding Up
Sep 05Improved Revenues Required Before Avacta Group Plc (LON:AVCT) Shares Find Their Feet
Jun 21Investors Give Avacta Group Plc (LON:AVCT) Shares A 26% Hiding
Feb 23Getting In Cheap On Avacta Group Plc (LON:AVCT) Is Unlikely
Aug 05Would Avacta Group (LON:AVCT) Be Better Off With Less Debt?
Jun 22We're Hopeful That Avacta Group (LON:AVCT) Will Use Its Cash Wisely
Oct 20This Is The Reason Why We Think Avacta Group Plc's (LON:AVCT) CEO Deserves A Bump Up To Their Compensation
Jun 22Avacta Group (LON:AVCT) Is In A Good Position To Deliver On Growth Plans
Jun 20Avacta Group Plc (LON:AVCT) Insiders Have Been Selling
Feb 18Companies Like Avacta Group (LON:AVCT) Are In A Position To Invest In Growth
Jan 23Opbrengsten en kosten
Hoe Avacta Group geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 23 | -26 | 21 | 15 |
31 Mar 24 | 23 | -25 | 20 | 15 |
31 Dec 23 | 23 | -25 | 20 | 15 |
30 Sep 23 | 20 | -32 | 21 | 13 |
30 Jun 23 | 16 | -40 | 22 | 11 |
31 Mar 23 | 13 | -38 | 20 | 11 |
31 Dec 22 | 10 | -37 | 19 | 11 |
30 Sep 22 | 8 | -31 | 17 | 12 |
30 Jun 22 | 7 | -25 | 15 | 13 |
31 Mar 22 | 5 | -26 | 14 | 13 |
31 Dec 21 | 3 | -26 | 13 | 13 |
30 Jun 21 | 2 | -20 | 9 | 12 |
31 Mar 21 | 2 | -18 | 9 | 10 |
31 Dec 20 | 2 | -16 | 9 | 9 |
30 Jun 20 | 5 | -12 | 8 | 7 |
31 Mar 20 | 4 | -12 | 8 | 6 |
31 Dec 19 | 4 | -11 | 7 | 6 |
31 Jul 19 | 4 | -10 | 8 | 6 |
30 Apr 19 | 3 | -10 | 8 | 5 |
31 Jan 19 | 2 | -10 | 8 | 5 |
31 Oct 18 | 3 | -9 | 8 | 4 |
31 Jul 18 | 3 | -9 | 7 | 3 |
30 Apr 18 | 3 | -8 | 7 | 3 |
31 Jan 18 | 3 | -7 | 8 | 3 |
31 Oct 17 | 3 | -7 | 7 | 3 |
31 Jul 17 | 3 | -6 | 7 | 3 |
30 Apr 17 | 3 | -6 | 7 | 2 |
31 Jan 17 | 2 | -6 | 7 | 2 |
31 Oct 16 | 2 | -5 | 6 | 2 |
31 Jul 16 | 2 | -5 | 5 | 2 |
30 Apr 16 | 2 | -5 | 5 | 1 |
31 Jan 16 | 2 | -5 | 5 | 0 |
31 Oct 15 | 2 | -5 | 4 | 0 |
31 Jul 15 | 2 | -5 | 4 | 0 |
30 Apr 15 | 2 | -4 | 4 | 0 |
31 Jan 15 | 2 | -3 | 4 | 0 |
31 Oct 14 | 2 | -2 | 3 | 0 |
31 Jul 14 | 2 | -1 | 3 | 0 |
30 Apr 14 | 2 | -1 | 3 | 0 |
31 Jan 14 | 2 | -1 | 3 | 0 |
Kwaliteitswinsten: AVCT is currently unprofitable.
Groeiende winstmarge: AVCT is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: AVCT is unprofitable, and losses have increased over the past 5 years at a rate of 20.7% per year.
Versnelling van de groei: Unable to compare AVCT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: AVCT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
Rendement op eigen vermogen
Hoge ROE: AVCT has a negative Return on Equity (-53.75%), as it is currently unprofitable.